# A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

> **NCT02220842** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 96 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Obinutuzumab
- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT02220842
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-18
- **Primary completion:** 2020-01-21
- **Final completion:** 2020-01-21
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02220842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02220842, "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02220842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*